

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/127, 37/22	A1	(11) International Publication Number: WO 91/04012 (43) International Publication Date: 4 April 1991 (04.04.91)
(21) International Application Number: PCT/US90/05292 (22) International Filing Date: 18 September 1990 (18.09.90) (30) Priority data: 410,608 21 September 1989 (21.09.89) US (71) Applicant: MICRO VESICULAR SYSTEMS, INC. [US/ US]; 20 Cotton Road, Nashua, NH 03063 (US). (72) Inventor: WALLACH, Donald, F., H. ; 94 Dow Road, Hol- lis, NH 03049 (US). (74) Agents: LOREN, Ralph, A. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).		(81) Designated States: AT (European patent), AU, BE (Euro- pean patent), BF (OAPI patent), BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (Euro- pean patent), CM (OAPI patent), DE (European pa- tent)*, DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (Eu- ropean patent), HU, IT (European patent), JP, KP, LU (European patent), ML (OAPI patent), MR (OAPI pa- tent), NL (European patent), NO, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PAUCILAMELLAR LIPID VESICLES USING CHARGE-LOCALIZED, SINGLE CHAIN, NONPHOSPHO- LIPID SURFACTANTS (57) Abstract Disclosed are paucilamellar lipid vesicles made of single chain nonphospholipid anionic or zwitterionic surfactants and a method of their manufacture. The preferred vesicle-forming materials are single chain sarcosinamides having 12-20 carbon chains and single chain betaines, the use of which obviates problems associated with using phospholipids as artificial membranes such as degradation by a large variety of enzymes, autocatalyzed peroxidation and high cost. The vesicles are formed rapidly and can be used to encapsulate aqueous or oily solutions. The vesicles may be used for transporting a whole spectrum of molecules, including macromolecules and drugs, vaccines, other therapeutic compositions and viruses, while some vesicles may act as adjuvants, carriers or storage devices for oil-based materials.		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TC	Togo
				US	United States of America

-1-

PAUCILAMELLAR LIPID VESICLES USING CHARGE-LOCALIZED,
SINGLE CHAIN, NONPHOSPHOLIPID SURFACTANTS

Reference to Related Applications

5 This application is a continuation-in-part
of United States Patent Application Serial No.
157,571, filed March 3, 1988, entitled "Paucilamellar
Lipid Vesicles", which is a continuation-in-part of
United States Patent Application No. 078,658, filed
10 July 28, 1987, now United States Patent No.
4,855,090, which itself is a continuation-in-part of
United States Patent Application Serial No. 025,525,
filed March 13, 1987, now abandoned, both entitled
"Method of Producing High Aqueous Volume
Multilamellar Vesicles," and United States Patent
15 Application Serial No. 124,824, filed November 25,
1987, entitled "Lipid Vesicles Formed of Surfactants
and Steroids." This application is also related to
United States Patent Application Serial No. 163,806,
entitled "Method and Apparatus for Producing Lipid
20 Vesicles".

Background of the invention

The present invention relates to the
production of paucilamellar lipid vesicles having
charge-localized, single chain nonphospholipid
25 zwitterionic or anionic surfactants as the primary
structural material of their lipid bilayers. More

- 2 -

particularly, the present invention relates to a method of producing these paucilamellar lipid vesicles having a large aqueous or organic liquid filled amorphous central cavity, as well as the
5 vesicles themselves.

Lipid vesicles are substantially spherical structures made of materials having a high lipid content, e.g., surfactants or phospholipids. The lipids of these spherical vesicles are organized in
10 the form of lipid bilayers. The lipid bilayers encapsulate an aqueous volume which is either interspersed between multiple onion-like shells of lipid bilayers, forming a classic multilamellar lipid vesicle ("MLV"), or the aqueous volume may be
15 contained within an amorphous central cavity. Common lipid vesicles having an amorphous central cavity filled with aqueous medium are the unilamellar lipid vesicles. Large unilamellar vesicles ("LUV"'s) generally have a diameter greater than about 1 μ while
20 small unilamellar lipid vesicles ("SUV"'s) generally have a diameter of less than 0.2 μ .

Paucilamellar lipid vesicles ("PLV"'s) are a hybrid having features of both MLV's and LUV's. PLV's are characterized by having 2-10 peripheral
25 bilayers surrounding a large, unstructured central cavity.

The potential utility of liposomes is widely recognized. Their ability to encapsulate aqueous volumes and/or lipophilic material makes them
30 attractive devices for transporting a whole spectrum of molecules, including macromolecules and drugs,

- 3 -

vaccines, and other therapeutic compositions. In addition, it is possible to encapsulate supramolecular structures such as viruses using classes of liposomes. Some types of vesicles have
5 shown an ability to act as adjuvants or as carriers or storage devices for oil-based materials.

Each type of lipid vesicle appears to have certain uses for which it is best adapted. For example, the multiple onion-like lipid bilayers of
10 classic MLV's provide this lipid vesicle with increased durability and protection from enzymatic degradation. The multiple shells greatly diminish the volume available for aqueous solutions to be encapsulated within the bilayers of the MLV. MLV's
15 have heretofore been deemed most advantageous for carrying lipophilic materials which can be incorporated in their bilayers. However, there is a maximum amount of lipophilic material that can be incorporated into MLV bilayers, beyond which the
20 bilayers become unstable and these vesicles break down. In contrast, the single shell of LUV's allow the encapsulation of a larger volume of aqueous material but because of their single lipid bilayer structure, LUV's are not as physically durable as
25 MLV's. SUV's have neither the lipid or aqueous volumes of MLV's or LUV's, but because of their small size have easiest access to cells and tissues.

PLV's appear to have advantages as transport vehicles for many uses as compared with the other
30 types of lipid vesicles. In particular, because of their large unstructured central cavity, PLV's are easily adapted for transport of large quantities of

aqueous-based materials. However, their multiple lipid bilayers provide PLV's with the ability to carry lipophilic material in their bilayers as well as with additional physical strength and resistance to degradation as compared with the single lipid bilayer of the LUV. In addition, as illustrated in the present application and United States Patent Application Serial No. 157,571, the disclosure of which is incorporated herein by reference, the central cavity of the PLV's can be filled wholly or in part with an apolar oil or wax and then can be used as a vehicle for the transport or storage of hydrophobic materials. Thus, the amount of hydrophobic material which can be transported by PLV's with an apolar core is much greater than can be transported by classic MLV's.

Early lipid vesicle or liposome studies used phospholipids as the lipid source for bilayers, primarily because phospholipids are the principal structural components of natural membranes. However, there are a number of problems associated with using phospholipids as artificial membranes. First, isolated phospholipids are subject to degradation by a large variety of enzymes. Second, the most easily available phospholipids are those from natural sources, e.g., egg yolk lecithin, which contain polyunsaturated acyl chains that are subject to autocatalyzed peroxidation. When peroxidation occurs, the lipid structure breaks down, causing premature release of encapsulated materials and the formation of toxic peroxidation byproducts. This problem can be avoided by hydrogenation but

- 5 -

hydrogenation is an expensive process, thereby raising the cost of the starting materials. Cost is a third problem associated with the use of phospholipids on a large scale. The high cost of a 5 kilogram of egg yolk lecithin pure enough for pharmacological liposome production places a severe limitation on the use of phospholipids as a source material.

It is now known that commercially available 10 surfactants may be used to form the lipid bilayer in a variety of lipid vesicles. (See, e.g., U.S. Patent Serial No. 4,217,344, U.S. Patent Serial No. 4,855,090, and U.S. Patent Application Serial No. 157,571). Both surfactants and phospholipids are 15 amphiphiles, having at least one lipophilic acyl or alkyl group attached to a hydrophilic head group. The head groups are attached to one or more lipophilic chains by ester, ether or amide linkages. Commercially available surfactants include the BRIJ 20 family of polyoxyethylene fatty acid ethers, the SPAN sorbitan alkyl esters, and the TWEEN polyoxyethylene sorbitan fatty acid esters, all available from ICI Americas, Inc., of Wilmington, Delaware. Unlike phospholipids, these surfactants are generally 25 nonionic, and addition of a charge-producing amphiphile is usually required to prevent flocculation and to increase the degree of encapsulation of water-soluble substances. Addition of a charge-producing amphiphile is not required if the 30 primary wall lipid is anionic -- as in the case of sarcosinamides.

- 6 -

In addition, the presence of a sterol or sterol-like molecule in the lipophilic phase used to create the lipid bilayer has often been found to be important for increasing the stability of the bilayer and hence the vesicle.

In 1982, Murakami et al. disclosed the preparation of small (.05-.2 μ), single- or multiple-walled vesicles capable of encapsulating aqueous volumes, using cationic and zwitterionic double chain amphiphiles synthesized to mimic the structure of naturally occurring phospholipids. The aqueous-carrying capacity of these vesicles is unknown as is their structure and stability. Murakami does not mention the possibility of oil encapsulation or single chain varieties of these ionic lipids.

The use of anionic or zwitterionic surfactants as cleaning or conditioning agents in cleansers such as shampoos is well documented in the art (see e.g., U.S. Patent Serial No. 4,075,131 and U.S. Patent Serial No. 4,832,872). However, in their present formulation in cleanser compositions, these surfactants are not present in vesicle form.

Recently an improved method for creating large aqueous volume MLV's and PLV's using commercially available, synthetic, nonionic surfactants has been discovered. U.S. Patent No. 4,855,090, and U.S. Patent Application Serial No. 157,571 disclose this new method which has the advantage of being faster and more cost-efficient

- 7 -

than previous methods. This improved method of creating PLV's and large aqueous volume MLV's, which is applicable to only certain surfactants, forms vesicles in less than a second rather than the 5 minutes or hours of classical techniques. Moreover, the improved method allows vesicles to be formed without the use of solvents and without the formation of a separable lamellar phase. These techniques, and the devices to utilize them, have only been described 10 in the aforementioned patents, as well as the related applications. In contrast, the classic methods for producing multilamellar lipid vesicles are well-documented in the art. See for example Gregoriadis, G., ed. Liposome Technology (CRC, Boca 15 Raton, FL), Vols. 1-3 (1984), and Dousset and Douste-Blzay (in Les Liposomes, Puisieux and Delattre, ed., Techniques et Documentation Lavoisier, Paris, pp. 41-73 (1985).

No matter how the MLV's or PLV's are formed, 20 once made it is necessary to determine the effectiveness of the process. Two measurements commonly used to determine the effectiveness of encapsulation of materials in lipid vesicles are the encapsulated mass and captured volume. The 25 encapsulated mass is the mass of the substance encapsulated per unit mass of the lipid and is often given as a percentage. The captured volume is defined as the amount of the aqueous phase trapped inside the vesicle divided by the amount of lipid in 30 the vesicle structure, normally given in ml liquid/g lipid.

- 8 -

The methods and materials disclosed herein for producing paucilamellar lipid vesicles formed of single chain charge-localized nonphospholipid zwitterionic or anionic surfactants all yield stable vesicles capable of encapsulating aqueous or oil volumes.

Accordingly, an object of the invention is to provide stable paucilamellar lipid vesicles from charge-localized non-phospholipid single chain surfactants.

Another object of the invention is to provide a method for producing such paucilamellar lipid vesicles which is rapid and uses relatively inexpensive materials.

A further object of the invention is to provide a vehicle for the transport of aqueous or oil-soluble materials formed essentially of charge-localized nonphospholipid single chain zwitterionic or anionic surfactants.

These and other objects and features of the invention will be apparent from the detailed description and the claims.


Summary of the Invention

The present invention features paucilamellar lipid vesicles whose primary lipid bilayer structural material is charge-localized single chain nonphospholipid material such as betaines or anionic

- 9 -


sarcosinamides, for use as carriers of hydrophilic or hydrophobic materials, and a method for their manufacture. A "charge-localized" molecule, as defined herein is a molecule containing a separation
 5 of charge so that a positive charge is located at one portion of the molecule while a negative charge is located at a different portion -- for example, a zwitterionic or an ionic molecule which has an associated counter-ion.

10 The method of the present invention for making paucilamellar lipid vesicles has the steps of forming a lipophilic phase of a single chain nonphospholipid zwitterionic or anionic surfactant and any other lipid soluble materials being
 15 incorporated in the bilayers of the vesicle which are dissoluble in the surfactant. Zwitterionic paucilamellar lipid vesicles are preferably made from surfactants selected from the group consisting of betaines having the structure




25 where R_2 is a long chain fatty acid ester. A preferred betaine is oleoyl propyl betaine, where R_2 has the structure

- 10 -



Anionic surfactants preferred in the
 5 invention are selected from the group consisting of
 sarcosinamides having the formula



10



where (R₁-C-) is the carbonyl derivative of
 a long chain fatty acid having 12 to 20 carbon
 atoms. Preferred sarcosinamides include the
 15 sarcosinamides of lauric acid, oleic acid, or
 methyl-sarcosinamides of mixed fatty acids having
 14-20 carbon atoms, e.g., the methyl-sarcosinamides
 of fraction 3 of coconut oil.

The lipophilic phase, which may contain
 20 charge-producing materials and/or sterols such as
 cholesterol or hydrocortisone or their analogs and
 derivatives, is blended with an aqueous phase
 consisting of an aqueous buffer and any
 aqueous-soluble materials to be encapsulated, under
 25 shear mixing conditions, to form the paucilamellar
 lipid vesicles. "Shear mixing" is defined as the
 mixing of the lipophilic phase with the aqueous phase

- 11 -

under turbulent or shear conditions which provide adequate mixing to hydrate the lipid and form lipid vesicles. "Shear mixing" is achieved by liquid shear which is substantially equivalent to a relative flow rate for the combined phases of about 5-30 m/s through a 1 mm orifice.

The invention further features the encapsulation of oil-soluble or oil-suspendable materials within these paucilamellar lipid vesicles.

10 This procedure commences with dispersing the material to be encapsulated in an oil or wax, forming an oily phase. The oil or wax is a water immiscible oily solution selected from a group consisting of oils, waxes, natural and synthetic triglycerides, acyl

15 esters, and petroleum derivatives, and their analogs and derivatives. The terms "disperse" or "dispersion" as used herein include dissolution or forming a suspension or colloid to yield a flowable phase. The oily phase containing the oil-dispersible

20 material is mixed with the lipid phase and the combined oil-lipid phase is blended under shear mixing conditions with the aqueous phase. Surfactants useful in the encapsulation process are the same as those used to make the aqueous-filled

25 paucilamellar lipid vesicles described above.

In order to achieve the proper blending necessary to form paucilamellar lipid vesicles of this invention, all of the materials are normally in a flowable state. This is easily achieved by

30 elevating the temperature of the lipophilic phase in order to make it flowable followed by carrying out

- 12 -

the shear mixing between the lipophilic phase and the aqueous phase at a temperature such that both phases are liquids. The surfactants of this invention are such that only gentle heating is required to obtain 5 flowability. While it is often desirable to use the same temperature for both phases, this is not always necessary.

Detailed Description of Preferred Embodiments

The present invention relates to the 10 production of zwitterionic and anionic paucilamellar lipid vesicles and the zwitterionic or anionic paucilamellar lipid vesicles themselves. These lipid vesicles, which have a single chain, nonphospholipid charge-localized surfactant material as their primary 15 structural component, are characterized by having 2-10 lipid bilayers with a small aqueous volume separating each substantially spherical lipid shell, surrounding a large amorphous central cavity. The cavity can be filled with an oil (including a wax), 20 an aqueous-based solution or some mixture thereof.

For certain uses, the incorporation of a charge-producing amphiphile or a sterol may be desired. Preferred charge-producing amphiphiles include dicetyl phosphate, cetyl sulfate, long chain 25 fatty acids, retinoic acid, carboxylic acids, quaternary ammonium compounds, and derivatives thereof. Cholesterol or one of its derivatives is a preferred sterol.

- 13 -

The paucilamellar lipid vesicles can be made by a variety of devices which provides sufficiently high shear for shear mixing. There are a large variety of these devices available on the market including a microfluidizer such as is made by Biotechnology Development Corporation, a "French"-type press, or some other device which provides a high enough shear force and the ability to handle heated, semiviscous lipids. If a very high shear device is used, it may be possible to microemulsify powdered lipids, under pressure, at a temperature below their normal melting points and still form the lipid vesicles of the present invention.

A device which is particularly useful for making the lipid vesicles of the present invention has been developed by Micro Vesicular Systems, Inc., Vineland, New Jersey and is further described in United States Patent Application Serial No. 163,806. Briefly, this device has a substantially cylindrical mixing chamber with at least one tangentially located inlet orifice. One or more orifices lead to a reservoir of the lipophilic phase, mixed with an oil phase if lipid-core PLV's are to be formed, and at least one of the other orifices is attached to a reservoir for the aqueous phase. The different phases are driven into the cylindrical chamber through pumps, e.g., positive displacement pumps, and intersect in such a manner as to form a turbulent flow within the chamber. The paucilamellar lipid vesicles form rapidly, e.g., in less than 1 second, and are removed from the chamber through an axially

- 14 -

located discharge orifice. In a preferred embodiment, there are four tangentially located inlet orifices and the lipid and aqueous phases are drawn from reservoirs, through positive displacement pumps, to alternating orifices. The fluid stream through the tangential orifices is guided in a spiral flow path from each inlet or injection orifice to the discharge orifice. The flow paths are controlled by the orientation or placement of the inlet or injection orifices so as to create a mixing zone by the intersection of the streams of liquid. The pump speeds, as well as the orifice and feed line diameters, are selected to achieve proper shear mixing for lipid vesicle formation. As noted, in most circumstances, turbulent flow is selected to provide adequate mixing.

The invention, and its many uses, will be more apparent from the following, non-limiting examples.

20 Example 1:

In this example three different sarcosinamides are tested for their ability to form paucilamellar lipid vesicles in the presence and absence of cholesterol and oleic acid, and for their ability to encapsulate an aqueous solution.

Table 1 lists the materials used and the results. The presence or absence of cholesterol (C) is indicated by a positive (+) or negative (-) sign. All sarcosinamides are obtained from R.T. Vanderbilt

- 15 -

Company, Inc. (Norwalk, CT): Vanseal LS ("LS") is the sarcosinamide of lauric acid, Vanseal OS ("OS") is the sarcosinamide of oleic acid, and Vanseal CS ("CS") is a methyl-sarcosinamide of fatty acids
5 derived from coconut oil - a mixture of mostly saturated C₁₄-C₂₀ carboxylic acids. The reactions are carried out in solutions having a pH such that less than 60% of the carboxyl groups are dissociated (pH range 3-5.5). Although syringes are used to
10 provide the shear mixing in this and the following examples, any shear-producing device which provides shear mixing can be used.

• One ml of the lipophilic phase formed of the surfactant (and additives, when present) is placed in
15 a 10 ml syringe and heated to 45°C, a temperature above the melting point of the surfactant. The lipophilic phase which results after the heating and blending of the lipophilic component(s) is forcibly injected, via a three-way stop-cock, into 4 ml of an
20 aqueous phase. The aqueous phase (in this example, 4 mls of water) is contained in a 10 ml syringe, and is also at 45°C. The process of injection of the lipophilic phase into the aqueous phase takes less than five seconds. The resulting mixture is then
25 forced repeatedly between the syringes at a linear flow rate of 8-12 m/s through an orifice about 1 mm in diameter. The mixture is driven continuously back and forth between the two syringes for approximately 2 minutes, providing the shear mixing necessary to
30 make the paucilamellar lipid vesicles. A milky suspension containing the paucilamellar lipid vesicles results. The lipid vesicles are separated

- 16 -

by centrifugation at 10,000 rpm for 15 minutes in a Beckman Instrumental Co. J-21 centrifuge, forming a low density phase on top of the aqueous solution.

TABLE 1

5	Surfactant	C	H ₂ O Uptake	Diameter
			ml/g	(microns)
	LS	+	3.0	0.3
	LS	-	4.0	0.45
	OS	+	3.0	0.35
10	OS	-	4.0	0.60
	CS	+	3.0	0.26
	CS	-	2.5	0.40

Composition: surfactant/cholesterol = 33 mM/11 mM

As is evident from the results listed
15 in Table 1, all of these surfactants form water-encapsulating vesicles in the presence or absence of cholesterol. The diameters and encapsulated volumes are greater when vesicles are formed with surfactants alone.

Example 2:

In this example, mineral oil (Drakeol 19) is used to show oil encapsulation efficiency for the paucilamellar lipid vesicles of this invention. As 5 in the previous example, the surfactants tested are sarcosinamides of lauric acid, oleic acid and coconut oil fatty acids, and the lipophilic phase is formed with and without additives.

Table 2 lists the materials used, and the 10 results. As in Table 1, the presence or absence of additives is indicated by +/-.

As in Example 1, the surfactant (and cholesterol, when present) is placed in a 10 ml syringe and heated to 45°C, a temperature above the 15 melting point of the surfactant, forming 1 ml of the lipophilic phase. This surfactant mixture is then blended with different amounts of mineral oil in a series of experiments until post-encapsulation oil saturation is reached. The lipophilic phase of the 20 lipid and oil is then blended with 4 ml of water, using the syringe method of Example 1.

As is evident from Table 2, all of these surfactants are able to encapsulate oil in the presence or absence of cholesterol and oleic acid. 25 As in Example 1, diameters and volumes encapsulated are greater when vesicles are formed with surfactants alone.

- 18 -

TABLE 2

<u>Surfactant</u>	<u>C</u>	<u>Oil Uptake</u> <u>ml/g</u>	<u>Diameter</u> <u>(microns)</u>
CS	+	10	0.68
5 CS	-	18	0.84
LS	+	7	0.34
LS	-	12	0.50
OS	+	7	0.16
OS	-	7	0.30

10 Composition: surfactant/cholesterol = 33 mM/11 mM

Example 3:

In this example, the ability of oleoyl propyl betaine to encapsulate water or mineral oil (Drakeol 19) is measured. Materials and proportions
15 used are listed in Table 3.

TABLE 3

Oleoyl propyl betaine	33 mM
Cholesterol	15 mM
1 ml total lipid	

- 5 The example is performed following essentially the same protocol as those of Examples 1 and 2. The aqueous phase is 2 mls water.

TABLE 4

10	<u>H₂O Uptake</u>	<u>Diameter</u>
	(ml/g)	(μ)
	1.5	0.15
<hr/>		
<hr/>		
	<u>Oil Uptake</u>	<u>Diameter</u>
	(ml/g)	(μ)
	15-16	~1.9

- 20 -

The results, listed in Table 4, clearly show the ability of oleoyl propyl betaine to encapsulate aqueous or oil volumes.

The foregoing description is illustrative
5 only and those skilled in the art may find other materials and methods which accomplish the same results. Such other materials are included within the following claims.

What is claimed is:

- 21 -

1. A method of preparing aqueous-filled, paucilamellar lipid vesicles consisting essentially of the steps of:

5 A. Providing a solventless non-aqueous lipophilic phase comprising a single chain charge-localized nonphospholipid surfactant and any lipid-soluble materials to be incorporated in said lipid vesicle;

10 B. Providing an aqueous phase formed of an aqueous solvent and any aqueous soluble materials to be encapsulated; and


C. Combining said nonaqueous lipophilic phase with a substantial excess of said aqueous phase in a single step under shear mixing conditions;

15 whereby said aqueous-filled paucilamellar lipid vesicles are without the formation of a separable lamellar phase.

2. The method of claim 1 wherein said single chain charge-localized nonphospholipid surfactant is
20 selected from the group consisting of betaines and anionic sarcosinamides.

3. The method of claim 2 wherein said betaine comprises a betaine having the structure:

- 22 -




5

where R_2 is a long chain fatty acid ester.


4. The method of claim 3 wherein R_2 is propyl oleate, having the structure

10



5. The method of claim 2 wherein said sarcosinamide comprises a sarcosinamide having the structure

15



20

where $\text{R}_1\text{-C-}$ is the carbonyl derivative of a long chain fatty acid having 12 to 20 carbon atoms.

6. The method of claim 5 where R_1 is selected from the group consisting of lauric acid, oleic acid, and/or mixtures of fatty acids having 14-20 carbon atoms.

25

- 23 -

7. The method of claim 2 wherein said lipophilic phase further comprises a sterol.

8. The method of claim 7 wherein said sterol comprises cholesterol or a derivative thereof.

5 9. The method of claim 2 or claim 7 wherein said lipophilic phase further comprises a charge-producing amphiphile.

10 10. The method of preparing oil-filled paucilamellar lipid vesicles consisting essentially of the steps of:

15 A. Providing a solventless non-aqueous lipophilic phase comprising a charge-localized single chain nonphospholipid surfactant and any lipid-soluble materials to be incorporated in said lipid vesicle;


B. Providing an aqueous phase formed of an aqueous solvent and any aqueous soluble materials to be encapsulated; and

20 C. Combining said nonaqueous lipophilic phase with a substantial excess of said aqueous phase in a single step under shear mixing conditions;

whereby said single chain charge-localized nonphospholipid paucilamellar lipid vesicles are without the formation of a separable lamellar phase.

11. The method of claim 10 wherein said single chain charge-localized nonphospholipid surfactant is selected from the group consisting of betaines and anionic sarcosinamides.


5 12. The method of claim 11 wherein said betaine comprises a betaine having the structure:



10


where R_2 is a long chain fatty acid ester.

13. The method of claim 12 wherein R_2 is propyl oleate, having the structure



15

14. The method of claim 11 wherein said sarcosinamide comprises a sarcosinamide having the structure



20

- 25 -


O
||

where R_1-C- is the carbonyl derivative of a long chain fatty acid having 12 to 20 carbon atoms.

- 5 15. The method of claim 14 where R_1 is selected from the group consisting of lauric acid, oleic acid, and/or mixtures of fatty acids having 14-20 carbon atoms.
16. The method of claim 11 wherein said
10 lipophilic phase further comprises a sterol.
17. The method of claim 16 wherein said sterol comprises cholesterol or a derivative thereof.
18. The method of claim 11 or claim 16 wherein said lipophilic phase further comprises a
15 charge-producing amphiphile.
19. Aqueous-filled paucilamellar lipid vesicles consisting of 2-10 lipid bilayers in the form of substantially spherical shells separated by aqueous layers, said lipid bilayers comprising a
20 charge-localized single chain nonphospholipid surfactant as the primary lipid, and any lipid-soluble materials to be incorporated in said lipid vesicle bilayers.
20. The paucilamellar lipid vesicles of claim 19
25 wherein said single chain charge-localized nonphospholipid surfactant is selected from the group consisting of betaines and anionic sarcosinamides.


- 26 -

21. The paucilamellar lipid vesicles of claim 20 wherein said betaine comprises a betaine having the structure:




where R_2 is a long chain fatty acid ester.

22. The paucilamellar lipid vesicles of claim 21 wherein R_2 is propyl oleate, having the structure



23. The paucilamellar lipid vesicles of claim 20 wherein said sarcosinamide comprises a sarcosinamide having the structure



where $\text{R}_1\text{-C-}$ is the carbonyl derivative of a long chain fatty acid having 12 to 20 carbon atoms.

- 27 -

24. The paucilamellar lipid vesicles of claim 23 where R_1 is selected from the group consisting of lauric acid, oleic acid, and/or mixtures of fatty acids having 14-20 carbon atoms.

5 25. The paucilamellar lipid vesicles of claim 20 wherein said lipophilic phase further comprises a sterol.

26. The paucilamellar lipid vesicles of claim 25 wherein said sterol comprises cholesterol or a
10 derivative thereof.


27. The paucilamellar lipid vesicles of claim 20 or claim 25 wherein said lipophilic phase further comprises a charge-producing amphiphile.

28. An oil-filled paucilamellar lipid vesicles
15 consisting of 2-10 lipid bilayers in the form of substantially spherical shells separated by aqueous layers, said lipid bilayers surrounding a substantially oil-filled amorphous central cavity, said lipid bilayers comprising a charge-localized
20 single chain nonphospholipid surfactant as the primary lipid, and any lipid-soluble materials to be incorporated in said lipid vesicle bilayers.

29. The paucilamellar lipid vesicles of claim 28 wherein said single chain charge-localized
25 nonphospholipid surfactant is selected from the group consisting of betaines and anionic sarcosinamides.


- 28 -

30. The paucilamellar lipid vesicles of claim 29 wherein said betaine comprises a betaine having the structure:




where R_2 is a long chain fatty acid ester.

31. The paucilamellar lipid vesicles of claim 30 wherein R_2 is propyl oleate, having the structure



32. The paucilamellar lipid vesicles of claim 29 wherein said anionic sarcosinamide comprises a sarcosinamide having the structure



20




where $\text{R}_1\text{-C-}$ is the carbonyl group of a long chain fatty acid having 12 to 20 carbon atoms.

- 29 -

33. The paucilamellar lipid vesicles of claim 32 where R_1 is selected from the group consisting of lauric acid, oleic acid, and/or mixtures of fatty acids having 14-20 carbon atoms.
34. The paucilamellar lipid vesicles of claim 29
5 wherein said lipophilic phase further comprises a sterol.
35. The paucilamellar lipid vesicles of claim 34 wherein said sterol comprises cholesterol or a derivative thereof.
- 10 36. The paucilamellar lipid vesicles of claim 29 or claim 34 wherein said lipophilic phase further comprises a charge-producing amphiphile.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/05292

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ¹		
According to International Patent Classification (IPC) as to both National Classification and IPC INT. CL. (5): A61K 9/127; 37/22 U.S. CL: 264/4.1; 424/450; 428/402.2; 436/829		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ⁶	Citation of Document, ¹⁵ with Indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X	US, A, 4,789,633 HUANG ET AL. 06 December 1988 see abstract; col. 2, lines 40-59; col. 3, lines 40-45; col. 7, lines 27-42; and example 3.	1,19
A	US, A, 4,247,411 VANLERBERGHE ET AL 27 January 1981	1-36
A	US, A, 4,348,329 CHAPMAN 07 September 1982	1-36
A	US, A, 4,762,915 KUNG ET AL. 09 August 1988	1-36
A,P	US, A, 4,911,928 WALLACH	1-36
A	GB, A, 2,147,263 TAKAHASHI ET AL. 09 May 1985	1-36
A	J. ORG CHEM., VOL.43 PAGES 2137-2144, 1982, MURIKAMI ET., "PREPARATION OF STABLE SINGLE-COMPARTMENT VESICLES WITH CATIONIC AND ZWITTER-IONIC AMPHOPHILES INVOLVING AMINO ACID RESIDUES".	1-36
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁶ Special categories of cited documents: ¹³</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"d" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²		Date of Mailing of this International Search Report ³
19 NOVEMBER 1990		23 JAN 1991
International Searching Authority ¹		Signature of Authorized Officer ²⁰
ISA/US		 RICHARD D. LOVERING